<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839643</url>
  </required_header>
  <id_info>
    <org_study_id>AVM-01001</org_study_id>
    <nct_id>NCT01839643</nct_id>
  </id_info>
  <brief_title>Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women</brief_title>
  <official_title>Phase 1 Study of Assessment of Local Absortion of a Non-steroidal Antiinflammatory Drug (NSAID), Inhibitor of Cyclooxygenase 2 (COX-2) Meloxicam, Through a Vaginal Ring and Its Effect on Ovarian Cycle in Fertile Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Andromaco S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Chileno de Medicina Reproductiva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Andromaco S.A.</source>
  <oversight_info>
    <authority>Chile: Comité de Ética Científico</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators propose to assess if a non-hormonal agent is absorbed by a
      local route (vaginal) and observe the effect on follicular development.  This study will
      include 3 menstrual cycles, beginning with one menstrual control cycle, following by one
      menstrual cycle with meloxicam ring administration and finishing with another control
      menstrual cycle.

      Meloxicam will be administered via a vaginal ring in two doses of 2.4 g and 3.0 g/ ring
      during one menstrual cycle.  Safety study of absorption will be assessed.  Also the
      investigators will study the effect on follicular development and if it maintains ovarian
      cyclicity, as well as shown in recent study with oral administration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Number of participants with follicular rupture delay</measure>
    <time_frame>Participants will be followed for the duration of one menstrual cycle, an expected average of 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate effective dose of maximum local safety that causes a greater proportion of follicular rupture delays. when it is administered continously, starting on the day 5 +/- 1 of the cycle until next menses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of meloxicam via vaginal route</measure>
    <time_frame>An expected average of 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The AUC of meloxicam serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding patterns with meloxicam vaginal ring</measure>
    <time_frame>one menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of meloxicam via vaginal route</measure>
    <time_frame>An expected average of 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax of meloxiam serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of meloxicam via vaginal route</measure>
    <time_frame>An expected average of 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax of meloxicam serum levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Contraception</condition>
  <condition>Bleeding Pattern</condition>
  <arm_group>
    <arm_group_label>2.4 g meloxicam vaginal ring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal ring, 2.4 g, continuosly during one menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 g meloxicam vaginal ring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal ring, 3.0 g, continuosly during one menstrual cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam vaginal ring</intervention_name>
    <arm_group_label>2.4 g meloxicam vaginal ring</arm_group_label>
    <arm_group_label>3.0 g meloxicam vaginal ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fertile women

          -  Regular menstrual cycle

          -  Surgically sterilized

          -  Without breastfeeding

          -  Haemoglobin over 11g/dL

          -  Willing to participate in the study

        Exclusion Criteria:

          -  Allergy to meloxicam or other NSAID

          -  Allergy to silicone polymer

          -  Vaginal discharge non diagnosticated

          -  History of shock toxic syndrome

          -  History of : gastrointestinal, bleeding, renal, liver, heart, brain,clot, endocrine
             or pulmonary disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Chileno de Medicina Reproductiva (ICMER)</name>
      <address>
        <city>Santiago</city>
        <zip>8320165</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>http://www.icmer.org</url>
  </link>
  <results_reference>
    <citation>Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod. 2010 Feb;25(2):368-73. Epub 2009 Nov 19.</citation>
    <PMID>19933235</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
